[ad_1]
Ruiz pointed out, in an interview with Noticias Caracol, that there is still no certainty of the number of Colombians who “developed immunity or resistance against the virus,” and only with that figure will it be known which population is the one most at risk of having a re-outbreak.
However, he indicated that with the reopening there is a “latent probability” that there will be a new wave of massive cases of coronavirus, “but with less mortality“.
In that sense, the official pointed out in the middle that the possibility of returning to a quarantine remains; Everything will depend on the power with which coronavirus affects the country again, and the self-care that citizens have.
“I would say with greater precision than that possibility [la de volver a una cuarentena] It is not ruled out, which could occur, which will depend a lot on the intensity of what that second regrowth could be. […] Ruiz warned.
He added that self-care will be essential so that a possible regrowth does not force a return to extreme restrictive measures.
“Be absolutely disciplined with the protocols that are there to help us. We have to understand that they are to reduce the probability of infections; have the possibility to enjoy everyday life without having to return to compulsory isolation“, He stressed.
On this point, the minister stressed that Colombians have been “judicious” in adopting protection measures to avoid the coronavirus, and that the health system already has a broad capacity to deal with cases of reinfection: “For example, it went from a laboratory to 119, an intensive care capacity that rose from 5,400 ICU to almost 11,000 ”, he indicated.
As long as there is no immunization, the coronavirus remains a risk that, according to the expert Gabriel Jaramillo, who belonged to the group that designed the global strategy against malaria, will remain until 2023, when, according to him, the world will have a real plan vaccination.
The National Institute of Health and Invima have already given their authorization for the vaccine to be tested in Colombia, which is being developed by a laboratory sponsored by the pharmaceutical company Janseen, from Johnson & Johnson, to study its safety and efficacy.
Studies of the vaccine began to be carried out on September 21, in some 600 Colombians who applied as volunteers to test the injection.
[ad_2]
